Title: Pharmacology Section 13. Treatment of motor disorders Treatment of Alzheimer
1PharmacologySection 13. Treatment of motor
disordersTreatment of Alzheimers disease
- Marta Józwiak-Bebenista
- Department of Pharmacology
- Medical University of Lodz
- martia1_at_tlen.pl
2Parkinson's Disease
- PD belongs to a group of conditions called motor
system disorders - progressive neurologic disorder that affects
neurons in the part of the brain controlling
muscle movement. - 1-2 of population suffer from this condition
normal, AD, PD, PDdementia
3Symptoms of PD
- Primary symptoms of PD
- Tremor
- Muscle rigidity (stiffness or inflexibility)
- Bradykinesia (slowing of voluntary movement )
- Postural and gait abnormalities
4Causes of PD
- DA-ergic neurons in substantia nigra and corpus
striatum (nigrostriatal DA-ergic tract) are
destroyed - nigrostriatal DA-ergic tract - part of the
extrapyramidal system, responsible for motor
control - 80 of DA-eric neurons are damaged, the symptoms
of Parkinson disease appear.
5Causes of PD
- The striatum, is also rich in excitatory
cholinergic neurons that counteract the action of
dopamine. - This is the dopamine-acetylocholine balance
- the dopaminergic system inhibits the
acetylocholinergic system.
DA
ACh
6In Parkinsons disease
- dopaminergic neurons degenerate in nigro-striatal
dopaminergic tract and the inhibitory influence
of dopamine on the striatum is diminished,
resulting in increased activity of excitatory
cholinergic neurons.
7Causes of PD
- Parkinson's disease may result from a combination
of genetic and environmental factors. - Certain toxins, diseases (viral encephalitis,
small vascular lesions) and drugs may also cause
symptoms similar to those of PD. - - haloperidol (Haldol)
- - chlorpromazine (Thorazine)
- - metoclopramide (Reglan)
- - prochlorperazine (Compazine)
- - valproate (Depacon)
8Risk factors
- Age - PD usually affects people over the age of
50 - Genetic factors / Heredity
- Sex - Men are more likely to develop Parkinson's
disease than women are. - Exposure to pesticides and herbicides
- Reduced estrogen levels
- Reduced folate levels
9Treatment of PD
- There is no cure for PD, but a variety of
medications provide dramatic relief from the
symptoms!
- The strategy of treatment of PD rests on
- ?dopamine levels in nigro-striatal dopaminergic
tract - restoring the correct dopamine-acetylocholine
balance (through antagonizing the excitatory
effect of cholinergic neurons)
10Drugs used in PD
- Drugs, which restore the dopamine levels in
nigro-striatal dopaminergic tract - Levodopa (L-dopa) and carbidopa
- COMT inhibitors
- Dopamine agonists
- Amantadine
- Selegiline
- Drugs, which restore the dopamine-acetylocholine
balance - Anticholinergics
11Levodopa
- the most effective medication for Parkinsons
disease. - 70-80 of treated Parkinsons patients are on
levodopa therapy. - Standard release preparations
- - levodopa/carbidopa (Sinemet or Atamet)
- - levodopa/benserazide (Madopar)
- Prolonged release preparations
- - levodopa/carbiopa (Sinemet CR)
- - levodopa/benserazide (Madopar HBS)
12Levodopa
- Mechanism of actions
- dopamine doesn't cross
- the BBB!
- Levodopa metabolic
- precursor of DA easily
- penetrate the BBB into
- the CNS.
DOPA-decarboxylase
Levodopa
Dopamine
13DOPA decarboxylase inhibitors
- Levodopa combined with DOPA decarboxylase
inhibitors represent a significant improvement in
the treatment of PD. - Carbidopa
- Benserazide
- a smaller dose of levodopa is needed to treat
symptoms - nausea and vomiting often associated with
levodopa treatment are greatly reduced by the
presence of DOPA decrboxylase inhibitors.
14Levodopa
- Actions
- Levodopa reduces akinesia and
- rigidity, in smallest degree
- decreases tremor.
- Pharmacokinetics
- well absorbed upon oral administration.
- should be taken on empty
- stomach, 45 minutes before a
- meal. Foods inhibit the
- absorption from the gut of
- levodopa and its transport into
- the CNS.
- Interactions
- Vit. B6
- MAOIs
- Antidepressants
- Neuroleptics
- Hypotensive drugs
Levodopa loses therapeutic efficacy after a long
time of treatment. This means that the length of
time that each dose is effective begins to
decrease, leading to more frequent doses.
15Levodopa
- The adverse side effects
- CNS
- - visual and auditory hallucinations,
- - mood changes (depression, excitation).
- With increased dosing and prolonged use of
levodopa, patients experience - - dyskinesias (spontaneous, involuntary
movements) and "on-off" periods when the
medication will suddenly and unpredictably start
or stop working. - - insomnia and anxiety.
- Peripheral
- - nausea, vomiting
- - low blood pressure.
16COMT inhibitors
- represent a new class of Parkinson's medications
- they must be taken as an adjunct with
levodopa/carbidopa!
Entacapone (Comtan) Tolcapone (Tasmar)
17COMT inhibitors
- Side effects diarrhea, postural hypotension,
dyskinesias, insomnia, nausea, hallucinations,
anorexia, constipation . Tolcapone is hepatotoxic
- Interaction MAOIs
- Indication
- Tolcapone- reduces the frequency of the
on-offperiods (motor fluctuations) - Entacapone- secondary medication delays wearing
off by prolonging effectiveness of levodopa
(Stalevo)
18Dopamine agonists
- They mimic the effects of dopamine in the brain
- The older used in combination with levodopa
- The side effects
- similar to those of levodopa,
- although they are less likely
- to cause involuntary
- movements (dyskinesia) and
- more likely to cause
- hallucinations, confusion,
- nausea or orthostatic
- hypotension.
- Agonists available in the United States include
- bromocriptine (Parlodel)
- pergolide (Permax)
- New drugs
- pramipexole (Mirapex)
- ropinirole (Requip)
- The newer used alone, as the first-line side
effects similar to bromocriptine but they are
milder.
19Amantadine- Symmetrel
- Side effects
- difficulty in concentrating
- confusion, insomnia
- nightmares, agitation
- hallucinations
- leg swelling
- mottled skin
- antiviral drug
- Mechanism of actions
- enhences the syntesis and
- release of DA and improve
- Dopaminergic neurotransmission.
- Actions
- less efficacious than levodopa but it has fewer
side effects - has little effect on tremor but is more effective
than the anticholinergics against rigitidy and
bradykinesia
for people in the latter stages of Parkinson's
disease, if they have problems with dyskinesia
induced by levodopa
20Selegiline- Deprenyl
- selective IMAO-B
- an adjunct to levodopa therapy,
- prevent the break down of both naturally
occurring DA and DA formed from levodopa,
resulting in ?dopamine levels in the brain
- Side effects
- heartburn,
- nausea,
- dry mouth,
- dizziness
- risk for severe hypertension (only at high doses
of drug)
- Eldepryl - Atapryl - Carbex
has a mild antidepressant effect.
21Anticholinergics
- the main treatment for Parkinson's disease before
the introduction of levodopa. - Mechanism of actions
- the activity of Ach
- Actions
- - used as secondary- adjuvant medications.
- - they help control tremors in the early stages
of the disease.
- Adverse effects
- blurred vision, dry mouth, urinary retention)
- mental problems
- memory loss,
- confusion
- hallucinations.
- They are not used long-term due to their side
effects.
Biperiden HCL (Akineton), Benztropine mesylate
(Cogentin) Procyclidine (Kemadrin),
Trihexyphenidyl (Artane)
22Over the counter medications
- Free radicals or reactive oxygen species may be
harmful to cells and lead to their death. - Antioxidants protect nerve cells from oxidative
damage. - Neuroprotective treatments may be most helpful at
an early stage of PD.
23PharmacologySection 13. Treatment of
Alzheimers disease
- Marta Józwiak-Bebenista
- Department of Pharmacology
- Medical University of Lodz
- martia1_at_tlen.pl
24Alzheimers disease
- AD it is one of the dementing disorders, which
are a group of brain diseases that result in the
loss of mental and physical functions. - AD is a progressive disease of the brain that is
characterized by impairment of memory and a
disturbance in at least one other thinking
function (for example, language or perception of
reality).
25Symptoms of AD
- Cognitive symptoms
- - memory loss
- - disorientation
- - confusion
- - difficulty with reasoned thought
- - loss of language skills.
- Behavioral symptoms
- - agitation/anxiety
- - delusions/hallucinations
- - depression
- - insomnia
- - wandering
The severity of the symptoms increases over
time. The onset of AD is usually very slow and
gradual.
26Causes of AD
- Neuropathologic causes
- - beta-amyloid protein (amyloid plaques)
- - degeneration of cholinergic neurons
- - atrophy of NA,DA,5-HTergic neurons
- Large amount patologic proteins apolipoprotein
E, presenilins -
Inflammation. - traumatic head
injuries earlier in life.
27Causes of AD
- Age (10 of people over age 65 and 50 of
those over 85 have AD) - Genetic factors
- Abnormalities in the brain's neurotransmitters,
- ACh is a critical neurotransmitter in the process
of forming memories. - ACh is abundant in the nerve cells of the
hippocampus and cerebral cortex, the regions that
are devastated by AD.
28Treatment of AD
- There is no treatment that will stop or reverse
the symptoms of AD. - The used drugs attempt to slow the progression of
the disease. - These drugs work to maintain levels of
neurotransmitters in the brain! - To increase the activity of cholinergic system we
use
- 1. acetylocholine precursors (lecithin, choline)
- 2. ACh-esterase inhibitors (acetylcholinesterase,
an enzyme responsible for the destruction of
acetylcholine) - Tacrine (Cognex),
- Donepezil (Aricept),
- Rivastigmine (Exelon),
- Galantamine (Razadyne, Reminyl)
29Treatment of AD
- Side effects of tacrine
- abdominal cramps
- nausea
- polyuria
- diarrhea
- hepatotoxic
- The newer anticholinesterase inhibitors
donepezil, rivastigmine, galantamine are better
tolerated. - The main side effects are nausea, vomitimg,
diarrhea. - The newer anticholinesterase inhibitors have
proved beneficial in improving memory, and have
fewer side effects.
The newer drugs are not effective for everyone,
and their effectiveness is limited to the early
and middle stages of AD.
30Treatment of AD
- Memantine (Namenda)
- approved to treat moderate to severe AD,
- Its effects are independent of acetylcholine and
acetylcholinesterase. - by blocking the NMDA receptors and the effects of
glutamate, memantine may protect nerve cells from
excess stimulation by glutamate.
31Treatment of AD
- It is possible to reduce some of the common
emotional and behavioral symptoms associated with
AD. - Tranquilizers- reduce agitation, anxiety,
unpredictable behavior. - Benzodiazepines- improve sleeping patterns
- Antidepressants - treat depression.
- Other drugs
- selegiline
- antioxidants (vit. E, koenzym Q10)
- anti-inflammatory drugs indometacin (NSAIDs)
32Huntingtons disease
33Huntington's disease (HD) Huntington disease
Huntington's chorea chorea maior
- movement disorder associated with defects in the
basal ganglia - inherited neurological disorder
- appears during adult life
- one out of every 10,000 Americans has HD
34Pathophysiology of HD
- Imbalance of dopamine, acetylcholine, GABA
- and perhaps other neurotransmitter in the basal
ganglia. - overactivity in dopaminergic nigrostriatal
pathways - increased responsiveness of postsynaptic dopamine
receptors - deficiency of a neurotransmitter that normally
antagonizes dopamine.
35Pathophysiology of HD
- GABA and glutamic acid decarboxylase are reduced
in the basal ganglia of patients with HD. - Ach and choline acetyltransferase are reduced in
the basal ganglia of patients with HD. - Theses deficiencies reduce the inhibitory
influence on the nigrostriatal dopaminergic
neurons and lead to the dopamainergic
hyperactivity associated with Huntingtons
disease
36- The symptoms of HD are suppressed by drugs that
block dopaminergic receptors and worsened by
drugs that increase basal ganglia dopaminergic
activity.
37Treatment of HD
Reduction basal ganglia dopaminergic activity
- Drugs that deplete central
- dopamine stores by blocking
- entry into the neuronal
- storage vesicles
- reserpine (small doses of 0.25 mg daily no
longer used in the UK) - tetrabenazine
- The adverse effects
- hypotension, depression,
- sedation, gastrointestinal disturbances.
- Drugs that block the
- dopaminergic receptors
- phenothiazines (e.g. Perphenazine)
- butyrophenones (e.g. Haloperidol)
- The adverse effects
- restlessness, parkinsonism.
38Treatment of HD
- enhance central GABA or Ach activity
-
- no consistently beneficial response